Navigating the complex world of biotechnology, one cannot miss the seismic shifts being created by gene therapy. This emerging field is revolutionizing the biomedical landscape, offering unprecedented promises of treating, even curing, several previously untreatable genetic disorders. But it is not just the scientific community that is poised for change. The commercial market for gene therapy is flourishing too. This blog will delve into the intricate dynamics of the gene therapy market, providing a comprehensive know-how on the latest market size statistics. Armed with credible information and industry trends, we aim to shed light on the financial aspect of this scientific marvel, potentially assisting investors, researchers, and curious minds alike in understanding the potential growth and opportunities within this burgeoning sector.

The Latest Gene Therapy Market Size Statistics Unveiled

The gene therapy market was valued at USD 3.8 billion in 2020.

Delving into the compelling world of the gene therapy market, we find ourselves standing before an awe-inspiring figure of USD 3.8 billion – a testament to the market’s valuation in 2020. This lofty figure is more than just a number; it’s a snapshot that captures not merely the economic ramifications, but the very trajectory and scale of this revolutionary medical frontier. It serves as a clear testament of the market’s financial potential, indicating pervasive enthusiasm among investors and augmenting discussions around future market prospects. Moreover, it sets a concrete reference point that quantifies the market’s ability to adapt, grow and pioneer in the face of challenges. A behemoth at USD 3.8 billion, the gene therapy market is on an unrestrained upward course, relentlessly paving the way to an economically viable and clinically promising future.

The gene therapy market is projected to grow at a CAGR of 34.9% from 2021 to 2028.

The impressive projection of the gene therapy market, growing at a Compound Annual Growth Rate (CAGR) of 34.9% from 2021 to 2028, carries considerable weight. In the thrilling tableau of gene therapy market size statistics, this figure acts like a spotlight, illuminating the rapid pace of market development and leading us to anticipate a resounding symphony of growth. This crescendoing figure of 34.9% implies not just robust growth but a continual acceleration, which suggests that the gene therapy market could metamorphose into one of the healthcare industry’s most substantial sectors.

Drawing on this potent projection, we can imagine a future where gene therapies may be as commonplace as today’s medications, and where new economic opportunities bloom in response to the sector’s growth. Therefore, these figures paint a picture not just of a thriving industry, but also of the potential power of gene therapy to reshape our world’s health landscape.

By 2027, the global gene therapy market is expected to reach USD 10 billion.

The forecast for the global gene therapy market to soar to a value of USD 10 billion by 2027 not only highlights the financial potential of this cutting-edge sector, but also speaks volumes about the anticipated advancements in the biotechnology industry. The magnitude of this projection underscores the significance the world sees in gene therapy, positioning it as a key player in the fight against numerous genetic diseases. With such noteworthy commercial potency, these illuminating figures spell out a rallying call to investors, healthcare professionals, and researchers; urging them to be part of this transformative journey and to contribute to the rapid evolution of medical and genetic science.

In 2020, the North American gene therapy market size was USD 1.34 billion.

The vibrant thread of financial figures that underpins gene therapy trends is illuminated by the stunning revelation that the North American gene therapy market size hit an epic USD 1.34 billion threshold in 2020. This financial high watermark etches an indelible mark on the canvas of healthcare innovations, exhibiting the firepower this sector has ignited on the economic front. Harnessing this fact in a blog post about gene therapy market size statistics embeds a potent point of reference, driving home the enormity and growth potential of this dynamic industry. This yardstick resonates with both science enthusiasts and savvy investors alike, speak volumes about the significant medical strides we’ve made, as well as the ripe financial prospects awaiting cultivation in the fertile ground of gene therapy.

A significant proportion of the market, about 45%, is comprised of cancer gene therapy.

With a bullish 45% stranglehold on the market sphere, cancer gene therapy has indeed become the formidable juggernaut of the gene therapy industry. Such an imposing presence not only underscores the immense investment pouring into cancer research but also highlights the trust and expectation of a breakthrough that the market places on this revolutionary medical technology. Inevitably, this further solidifies the realization that cancer gene therapy is no longer a promising concept in theory but a real player driving the expansion of the gene therapy realm.

The Yescarta gene therapy is predicted to generate about USD 2.7 billion annually by 2026.

This projected revenue for Yescarta gene therapy paints an eloquent picture of the future financial landscape of the gene therapy market. Setting an estimated benchmark of USD 2.7 billion annually by 2026, it not only underscores the considerable growth potential this segment holds, but also signifies the increasing acceptance and demand for such advanced therapeutic measures. Within the context of market size, it provides a potent reference point, offering a glimpse into the profitable opportunities that await entrepreneurs, investors, and medical professionals alike in the gene therapy niche. So, in essence, Yescarta’s projected earnings embody the growth and advancement that the gene therapy market is bound to witness in the coming years.

The viral vector & plasmid DNA segment held the largest share in the gene therapy market in 2019.

Illuminating the landscape of the gene therapy market pops the spotlight onto the viral vector and plasmid DNA segment in 2019, occupying the most substantial chunk of this ever-evolving arena. Unpacking this captivating statistic, we dive into a pivotal insight that underpins the distribution of market shares. The prominence of this category alone signifies its irreplaceable role in the gene therapy market.

From a market intelligence perspective, this dominant position suggests a high level of acceptance and use in the medical and scientific communities, indicating its promising potential for future development and investment. Moreover, it underscores the increasing demand for these tools in driving forward the gene therapy research and therapeutic applications. Therefore, understanding which segment dominates the market share serves as a compass, navigation through the complexities of the gene therapy market landscape.

Europe’s gene therapy market was worth USD 792 million in 2019.

In the ever-evolving realm of gene therapy, the monetary metrics can provide a testimony to its growth curve. Taking a closer look at Europe, for instance, the worth of its gene therapy market stood at an impressive USD 792 million in 2019. Now this figure is not just a cold, hard number, but an economic imprint marking the significance of gene therapy in the medical science sector. It suggests the ongoing investments in research and development, the demand for such treatments, and the potential profitability in the European region. Moreover, this value is an essential baseline, offering an insight into how much the market is likely to expand or change in the future. Thus, it is a crucial piece in the puzzle of understanding gene therapy’s global market scenario.

It is predicted that by 2026, 16% of the gene therapy market will be made up of CAR T-cell therapy.

Forecasting forward to 2026, the gene therapy market is expected to shift with Car T-cell therapy claiming an impressive 16% share. This not only indicates momentum in the recognition and application of this particular gene modifying treatment, but also underscores the dynamic nature of the gene therapy landscape. For observers of the sector, clinicians, investors, or potential patients, this statistic may signal emerging opportunities and underpin strategic decision-making. It highlights significant growth potential for Car T-cell therapy and underlines how meaningful advancements in gene therapy techniques could mold the healthcare industry over the next five years.

The ophthalmology applications segment of gene therapy is projected to grow at a CAGR of 33.6% between 2021-2028.

Highlighting the astounding projection of a 33.6% CAGR within the ophthalmology applications segment of gene therapy between 2021-2028 essentially paints a picture of immense growth within the market. It signals a skyrocketing demand likely spurred by advancements in technology and increased incidences of eye-related genetic disorders. This hints at increasing consumer confidence and acceptance of gene therapy for ophthalmological ailments. Therefore, strategic decisions and investments directed towards this domain could potentially harvest rich dividends in the future. It serves as a key insight for players in the gene therapy market, guiding their focus towards ophthalmology as an area of promising opportunity, thus steering the direction of the gene therapy market size statistics.

In Asia-Pacific, the gene therapy market is expected to grow at a CAGR of 41.1% from 2020 to 2027.

Embedding this remarkable projection shows the massive potential the Asia-Pacific region holds for generating growth in the gene therapy market. Highlighted by the noteworthy 41.1% CAGR from 2020 to 2027, it informs readers of the enormous momentum that this particular market is predicted to gain over time. The statistic is an indicator of the multitude of investment opportunities, substantial profitability prospects, and innovative developments about to unfold in the Asia-Pacific gene therapy sector. Thus, it is a crucial market aspect to be aware of for anyone engrossed in this field’s landscape and market dynamics.

The hospital segment accounted for the largest share of over 60% in the global gene therapy market in 2019.

Delving into the intriguing narrative of the gene therapy market, one can’t help but highlight the dominant figure of hospital segments, capturing a hefty share of over 60% in the global arena in 2019. This commanding hold is much like a lighthouse, casting light on important areas for analysis and consideration. It suggests that hospitals play an unsurprisingly pivotal role in performing these cutting-edge procedures that continue to re-engineer the medical landscape. This information, thus, underscores the prevalence of such advanced treatments in conventional healthcare institutions, further fuelling market traction. Moreover, it provides a clear indication for potential investors about where the bulk of activity lies within this market, guiding strategic planning and resource allocation. It also sparks conversation about possible consumer preferences, availability, and accessibility of this revolutionary medical treatment, and the ever-evolving dynamics of healthcare facilities’ contribution to this burgeoning sector.

The in vivo gene therapy segment had a market share of 56.8% in 2020.

Delving into the world of gene therapy, we land upon a fascinating revelation. The in vivo gene therapy segment held a considerable dominion in the year 2020, clutching the lion’s share with a whopping 56.8% of the total gene therapy market. This piece of information is like the North Star, illuminating the extent of market penetration and influence this particular segment wielded.

The prevailing dominance of the in vivo gene therapy unveils intriguing trends that conceivably underpin the entire market dynamics. This stratospheric figure serves as an indicator of growing therapeutic potential, increased application of the method, and likely, market preferability towards in vivo techniques.

In the grand tapestry of the gene therapy market vicinity, this illuminates not just the market’s present stature, but it also adds vital insights that can act as a launchpad for forecasts, strategies, and future market trends. Thus, this revelation is far more than just a statistic – it’s a translator of industry patterns, a barometer of market traction, and essentially, a crystal ball foreseeing future prospects in the gene therapy niche.

By 2030, the global gene therapy market for rare diseases is expected to be worth approximately USD 7.6 billion.

The vision of the future surrounding the gene therapy market, particularly for rare diseases, is compellingly painted by the prediction of a worth of approximately USD 7.6 billion by 2030. This prospective valuation is not just a reflection of substantial financial growth, but it also signifies the increasing relevance, recognition, and potential of gene therapies in the healthcare domain.

Such an impressive market size points towards the robustness and vitality gene therapies will acquire, impacting the development of treatments and cures for rare conditions. The statistic ultimately serves as the evidence of the progressive integration of gene therapies into mainstream medical discourse and practice, demonstrating the substantial promise it holds in revolutionizing healthcare by 2030.


In summary, the projected growth of the gene therapy market size represents a promising avenue in the healthcare sector. Robust research and development activities, technological advancements, and increasing investments are expected to be the fueling factors for this expansion. As promising as the future looks, it’s also important to acknowledge potential challenges and uncertainties such as regulatory hurdles and safety concerns. Despite this, the substantial progress in gene therapy has created immense potential for treating various genetic disorders, and this promising field is evidently on a steady upward trajectory. The rising trend in market statistics envisions a future where gene therapy bridges the gap between science and improved human health.


0. –

1. –

2. –

3. –

4. –

5. –

6. –

7. –

8. –

9. –